论文信息 - Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.

Progression of LNCaP prostate tumor cells during androgen deprivation: hormone-independent growth, repression of proliferation by androgen, and role for p27Kip1 in androgen-induced cell cycle arrest.

The molecular mechanism of androgen-independent growth of prostate cancer after androgen ablation was explored in LNCaP cells. An androgen-dependent clonal subline of the LNCaP human prostate carcinoma cell line, LNCaP 104-S, progressed to a slow growing stage (104-R1) and then to a faster growing stage (104-R2) during more than 2 yr of continuous culture in the absence of androgen. Androgen-induced proliferation of 104-S cells is inhibited by the antiandrogen Casodex, while proliferation of 104-R1 and 104-R2 cells is unaffected by Casodex. This indicates that proliferation of 104-R1 and 104-R2 cells is not supported by low levels of androgen in the culture medium. Compared with LNCaP 104-S cells, both 104-R1 and 104-R2 cells express higher basal levels of androgen receptor (AR), and proliferation of these two cell lines is paradoxically repressed by androgen. After continuous passage in androgen-containing medium, 104-R1 cells reverted back to an androgen-dependent phenotype. The mechanism of androgenic repression of 104-R1 and 104-R2 sublines was further evaluated by examining the role of critical regulatory factors involved in the control of cell cycle progression. At concentrations that repressed growth, androgen transiently induced the expression of the cyclin-dependent kinase (cdk) inhibitor p21waf1/cip1 in 104-R1 cells, while expression of the cdk inhibitor p27Kip1 was persistently induced by androgen in both 104-R1 and 104-R2 cells. Induced expression of murine p27Kip1 in 104-R2 cells resulted in G1 arrest. Specific immunoprecipitates of Cdk2 but not Cdk4 from androgen-treated 104-R1 cells contained both p21waf1/cip1 and p27Kip1. This observation was confirmed by in vitro assay of histone H1 and Rb (retinoblastoma protein) phosphorylation by the proteins associated with the immune complex. Furthermore, inhibition of Cdk2 activity correlated with the accumulation of p27Kip1 and not p21waf1/cip1. From these results we conclude that androgenic repression of LNCaP 104-R1 and 104-R2 cell proliferation is due to the induction of p27Kip1, which in turn inhibits Cdk2, a factor critical for cell cycle progression and proliferation.

[1] K. Horwitz,et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). , 1997, Molecular endocrinology.

[2] J. Kim,et al. Transforming growth factor-beta1 is a mediator of androgen-regulated growth arrest in an androgen-responsive prostatic cancer cell line, LNCaP. , 1996, Endocrinology.

[3] R. Weinberg,et al. The retinoblastoma protein and cell cycle control , 1995, Cell.

[4] L. Nazareth,et al. Activation of the Human Androgen Receptor through a Protein Kinase A Signaling Pathway* , 1996, The Journal of Biological Chemistry.

[5] M. Gleave,et al. Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gene in the LNCaP prostate tumour model , 1996, The Journal of Steroid Biochemistry and Molecular Biology.

[6] N. Hay,et al. Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-term androgen deprivation. , 1994, Cancer research.

[7] M. Pagano,et al. Enhanced Ribosomal Association of p27Kip1 mRNA Is a Mechanism Contributing to Accumulation during Growth Arrest* , 1997, The Journal of Biological Chemistry.

[8] M. Blankenstein,et al. Effect of culture conditions on androgen sensitivity of the human prostatic cancer cell line LNCaP , 1993, The Prostate.

[9] R. Hiipakka,et al. Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[10] K. Ito,et al. Expression and function of normal and LNCaP androgen receptors in androgen-insensitive human prostatic cancer cells. Altered hormone and antihormone specificity in gene transactivation. , 1991, Receptor.

[11] I. Roninson,et al. Inducible retroviral vectors regulated by lac repressor in mammalian cells. , 1996, Gene.

[12] N. Sato,et al. Loss of androgen dependency with preservation of functional androgen receptors in androgen-dependent mouse tumor (Shionogi carcinoma 115) , 1992, The Journal of Steroid Biochemistry and Molecular Biology.

[13] N. Sato,et al. Progression of Androgen‐sensitive Mouse Tumor (Shionogi Carcinoma 115) to Androgen‐insensitive Tumor after Long‐term Removal of Testosterone , 1993, Japanese journal of cancer research : Gann.

[14] C. Huggins,et al. STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[15] D. Peehl,et al. 1α,25-Dihydroxyvitamin D3 Actions in LNCaP Human Prostate Cancer Cells Are Androgen-Dependent. , 1997, Endocrinology.

[16] K. Fujimori,et al. Enhanced expression of a glyceraldehyde-3-phosphate dehydrogenase gene in human lung cancers. , 1987, Cancer research.

[17] W. Qian,et al. Progression to androgen insensitivity in a novelin vitro mouse model for prostate cancer , 1995, The Journal of Steroid Biochemistry and Molecular Biology.

[18] J. Trapman,et al. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. , 1997, Molecular endocrinology.

[19] S. Ōmura,et al. Proteasome-dependent regulation of p21WAF1/CIP1 expression. , 1996, Biochemical and biophysical research communications.

[20] Schr,et al. Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[21] S. Lowe,et al. Oncogenic ras Provokes Premature Cell Senescence Associated with Accumulation of p53 and p16INK4a , 1997, Cell.

[22] T. Visakorpi,et al. Genetic changes associated with the acquisition of androgen-independent growth, tumorigenicity and metastatic potential in a prostate cancer model. , 1997, British Journal of Cancer.

[23] F. Schröder,et al. The human prostatic cancer cell line LNCaP and its derived sublines: An in vitro model for the study of androgen sensitivity , 1991, The Journal of Steroid Biochemistry and Molecular Biology.

[24] D. Wolf,et al. Synthetic androgens suppress the transformed phenotype in the human prostate carcinoma cell line LNCaP. , 1991, British Journal of Cancer.

[25] J. Short,et al. Modifications of the E.coli Lac repressor for expression in eukaryotic cells: effects of nuclear signal sequences on protein activity and nuclear accumulation. , 1992, Nucleic acids research.

[26] L. Chung,et al. Androgen-repressed phenotype in human prostate cancer. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[27] G. Jenster,et al. A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. , 1990, Biochemical and biophysical research communications.

[28] Jorma Isola,et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer , 1995, Nature Genetics.

[29] W. Catalona,et al. Management of cancer of the prostate. , 1994, The New England journal of medicine.

[30] H. Klocker,et al. Distant metastases from prostatic carcinoma express androgen receptor protein. , 1995, Cancer research.

[31] J. Masters,et al. Comparison of testosterone metabolism in benign prostatic hyperplasia and human prostate cancer cell lines in vitro , 1994, The Journal of Steroid Biochemistry and Molecular Biology.

[32] William B. Isaacs,et al. Establishment and characterization of seven dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers , 1986 .

[33] H. Klocker,et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.

[34] J. Trent,et al. WAF1, a potential mediator of p53 tumor suppression , 1993, Cell.

[35] J. Veldscholte,et al. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. , 1992, Biochemistry.

[36] A. Coldman,et al. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. , 1990, Cancer research.

[37] L. Chung,et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.

[38] W. McGuire,et al. Estrogen control of progesterone receptor in human breast cancer. Correlation with nuclear processing of estrogen receptor. , 1978, The Journal of biological chemistry.